BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, we evaluated the ability of this in-house RQ-PCR method to detect low level BCR-ABL1 fusion transcripts using samples obtained in the ongoing Delightedly Overcome CML Expert Stop TKI (DOMEST) clinical trial to evaluate the rationale for cessation of imatinib [24].